Vaxart Announces Withdrawal of Reverse Stock Split Proposal
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced the withdrawal of its reverse stock split proposal. CEO Steven Lo emphasized that the company will maintain frequent stockholder communication while focusing on advancing their oral pill vaccine platform technology.
The decision comes after receiving constructive feedback from stockholders, with management expressing commitment to creating long-term value through their proprietary vaccine delivery platform development.
Vaxart (OTCQX: VXRT), una empresa biofarmacéutica en fase clínica, specializzata in vaccini orali sotto forma di pillole ricombinanti, ha annunciato il ritiro della proposta di reverse stock split. Il CEO Steven Lo ha sottolineato che l’azienda continuerà a comunicare frequentemente con gli azionisti, concentrandosi allo tempo sull’avanzamento della piattaforma tecnologica dei vaccini somministrabili per via orale.
La decisione arriva dopo aver ricevuto feedback costruttivo da parte degli azionisti, e la direzione si impegna a creare valore a lungo termine attraverso lo sviluppo della piattaforma proprietaria di somministrazione dei vaccini.
Vaxart (OTCQX: VXRT), una empresa biofarmacéutica en fase clínica especializada en vacunas orales en formato de píldora recombinante, ha anunciado la retirada de su propuesta de segregación inversa de acciones. El CEO Steven Lo enfatizó que la compañía mantendrá una comunicación frecuente con los accionistas mientras se enfoca en avanzar su plataforma tecnológica de vacunas en píldoras orales.
La decisión se produce tras recibir comentarios constructivos de los accionistas, y la dirección se compromete a crear valor a largo plazo mediante el desarrollo de su plataforma propietaria de entrega de vacunas.
Vaxart (OTCQX: VXRT)는 경구용 재조합 알약 백신을 전문으로 하는 임상 단계의 생명공학 기업으로, 역주식 분할 제안의 철회를 발표했습니다. CEO 스티븐 로는 주주와의 빈번한 소통을 지속하는 한편 경구용 알약 백신 플랫폼 기술의 개발에 집중하겠다고 강조했습니다.
주주들로부터 건설적인 피드백을 받은 뒤 내려진 이번 결정은 독자적 백신 전달 플랫폼 개발을 통해 장기 가치를 창출하겠다는 경영진의 의지를 보여줍니다.
Vaxart (OTCQX : VXRT), une entreprise de biotechnologie en phase clinique spécialisée dans les vaccins sous forme de pilules recombinantes à administration orale, a annoncé le retrait de sa proposition de regroupement d’actions inversé. Le PDG Steven Lo a souligné que la société continuera de communiquer fréquemment avec les actionnaires tout en se concentrant sur l’avancement de sa plateforme technologique de vaccins sous forme de pilules orales.
Cette décision fait suite à des retours constructifs des actionnaires, et la direction s’engage à créer une valeur à long terme par le développement de leur plateforme exclusive de livraison de vaccins.
Vaxart (OTCQX: VXRT), ein im klinischen Stadium befindliches Biotechnologieunternehmen, das sich auf orale rekombinante Pillenimpfstoffe spezialisiert hat, hat die Rücknahme seines Vorschlags für eine umgekehrte Aktienteilung angekündigt. CEO Steven Lo betonte, dass das Unternehmen den regelmäßigen Dialog mit den Aktionären fortsetzen wird, während man sich auf die Weiterentwicklung der Plattformtechnologie für orale Pillenimpfstoffe konzentriert.
Die Entscheidung erfolgte nach konstruktivem Feedback der Aktionäre, und das Management verpflichtet sich, durch die Entwicklung ihrer firmeneigenen Impfstoff-Abgabeplattform langfristigen Wert zu schaffen.
Vaxart (OTCQX: VXRT)، شركة تكنولوجيا حيوية في مرحلة التجارب السريرية تتخصص في لقاحات فموية على شكل أقراص مُعاد تركيبها، أعلنت سحب مقترحها لاقتسام الأسهم العكسي. وقد أكد الرئيس التنفيذي ستيفن لو أن الشركة ستستمر في التواصل بشكل متكرر مع المساهمين بينما تركّز على تعزيز منصة لقاحات الأقراص الفموية.
جاءت هذه الخطوة بعد تلقي تعليقات بناءة من المساهمين، مع التزام الإدارة بخلق قيمة طويلة الأجل من خلال تطوير منصة توصيل اللقاحات المملوكة لها.
Vaxart (OTCQX: VXRT)，一家处于临床阶段、专注于口服重组药丸疫苗的生物技术公司，宣布撤回其反向股票拆分提案。首席执行官史蒂文·洛强调，公司将继续与股东保持频繁沟通，同时专注于推进其口服药丸疫苗平台技术的发展。
这一决定是在股东给出建设性反馈后作出的，管理层承诺通过开发其自有的疫苗递送平台来实现长期价值。
- Company demonstrates responsiveness to shareholder feedback by withdrawing reverse split proposal
- Management maintains focus on core vaccine platform development
- Company remains listed on OTCQX rather than major exchange
- Withdrawal suggests potential difficulty in gaining shareholder support for strategic initiatives
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, announced that it has withdrawn its reverse stock split proposal.
“After careful consideration, we have decided to officially withdraw our reverse stock split proposal. Moving forward, we will continue to communicate frequently with our stockholders across multiple channels,” said Steven Lo, Chief Executive Officer of Vaxart. “At the same time and more importantly, our team remains intensely focused on advancing the science behind our promising oral pill vaccine platform to create significant long-term value for all our stockholders.”
Vaxart’s Board and management team thanks its stockholders for their constructive feedback and looks forward to continued engagement.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are subject to the “safe harbor” created by those sections, concerning our business, operations, and financial performance and condition as well as our plans, objectives, and expectations for business operations, funding, any ability to stay listed on Nasdaq, any ability to regain and maintain compliance with the Bid Price Rule, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as “anticipate,” “assume,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this communication may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under “Item 1A - Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this communication. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this communication.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
Why did Vaxart (VXRT) withdraw its reverse stock split proposal in September 2025?
What is Vaxart's (VXRT) main business focus in 2025?
What did Vaxart CEO Steven Lo say about the company's future direction?
What exchange is Vaxart (VXRT) stock trading on in 2025?
How did Vaxart shareholders respond to the reverse split withdrawal?
